CHITROBACT

This brand name is authorized in Nigeria.

Active ingredients

The drug CHITROBACT contains a combination of these active pharmaceutical ingredients (APIs):

1	Betamethasone UNII 826Y60901U - BETAMETHASONE DIPROPIONATE
	Betamethasone is a glucocorticoid which is about eight to ten times as active as prednisolone on a weight-for-weight basis. Betamethasone has anti-inflammatory, antipruritic, and vasoconstrictive properties.
	Read more about Betamethasone
2	Ketoconazole UNII R9400W927I - KETOCONAZOLE
	Ketoconazole is an imidazole-dioxolane antimycotic, active against yeasts, including Malassezia and dermatophytes.
	Read more about Ketoconazole

Packages

This drug has been approved in Nigeria as follows:

Identifier	Form	Presentation	Description	Approval
A4-100809	Cream	Chitrobact Cream CREAM 0.05%; 2% 1 X 30MG	62 NF-PP-394944 Chitrobact Cream Betamethasone Dipropionate 0.05% and Ketoconazole 2% White Soft Paraffin BP Moisturizer ----- 4500 45 2 Cetostearyl Alcohol BP Opacifying Agent ----- 2400 24 3 Cetomacragol 1000 IH Solubilize & emulsifying Agent ----- 600 6 , Sodium Methyl Paraben BP Preservative ----- 30 0.3 5 Sodium Propyl Paraben BP Preservative ----- 30 0.3 6 Di Sodium Edetate BP Chelating Agent ----- 30 0.3 7 Para Chloro Meta Cresol BP Preservative ----- 30 0.3 , Ketoconazole BP Active A4-100809 Drugs Imported Products 1x30mg Prescription Only Medicine (POM) PAL - PHARMACEUTICAL INDUSTRIE LIMITED, 102, Maganda Road, Bompai Industries Area, Kano, Kano State 8070777770 emypal@yahoo.com FLOURISH PHARMA, 24 E GOA IDC DAMAN INDUSTRIAL ESTATE, SOMNATH DABHEL DAMAN 396215, India	30/04/2024

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D07CC01	Betamethasone and antibiotics	D Dermatologicals → D07 Corticosteroids, dermatological preparations → D07C Corticosteroids, combinations with antibiotics → D07CC Corticosteroids, potent, combinations with antibiotics
Discover more medicines within D07CC01

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
NG	Registered Drug Product Database	A4-100809